Calgary, Alberta – TheNewswire - September 4, 2025 – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE: NDAT) (OTCQB: NDATF) is pleased to announce the initiation of “Epitome”, a next-generation sports performance analytics project designed to apply advanced machine learning to professional hockey performance. The project builds upon nDatalyze’s clinically validated Emotional State/Performance assessment platform (https://sigmundml.com) and represents a strategic move into the fast-growing global sports analytics market, projected to surpass USD $22 billion by 2030.

Value Proposition

Epitome leverages proprietary biometric modeling technology to address one of the most financially consequential challenges in professional sports: accurately predicting athletic performance. With NHL teams investing millions in draft picks, trades, and long-term contracts, the ability to more reliably forecast player success could materially reduce risk and increase returns for franchises. By extension, this creates significant commercial potential for Epitome, positioning NDAT at the intersection of AI, genomics, and sports analytics.

Project Overview

• Signature Modeling: Epitome creates a unique “Signature” for each player by combining biometric data, performance statistics, genetic predispositions, and algorithmic scores. 

• Ground Truth Benchmarking: The system compares individual Signatures against those of proven high-performance players (forwards and defense) to establish predictive benchmarks. 

• Applications: 

  1. Assessing future performance prospects before acquisitions or trades. 

  2. Optimizing roster configurations to strengthen team performance. 

  3. Developing personalized coaching and training protocols to maximize player outcomes. 

Industry Demand & Economic Rationale
The risks associated with player drafting and development are well-documented. Only 19% of NHL draftees play more than 200 games, underscoring the billions of dollars lost to inefficiencies in talent selection. As Jim Durward, NDAT President, notes:

“The draft is an inherently risky, multimillion-dollar gamble. By adapting our clinically studied Sigmund algorithms for sports applications, we are building a valuation tool that may significantly de-risk these decisions. Our goal is to create a disruptive edge in professional hockey, with potential scalability across other major sports.”

Progress & Strategic Positioning

• NDAT has already secured commitments from three Advisors (two former NHL coaches and one University-level coach) to help define the digital “high-performance player”. Additional pathways to former NHL players are being developed. 

• The project is fully financed through existing cash on hand, ensuring no dilution to shareholders at this stage. 

• Importantly, the previously announced RTO continues to advance, with Epitome included in the proposed spinout. This means pre-RTO NDAT shareholders will directly benefit from the project whether or not the RTO closes. 

Epitome underscores NDAT’s commitment to commercializing its proprietary AI-driven biometric technology across multiple high-value verticals. By targeting a multi-billion dollar global market with a unique, clinically grounded solution, NDAT believes Epitome has the potential to deliver meaningful shareholder value while positioning the Corporation as a leader in the convergence of AI and predictive sports performance analytics.

 

For Further Information, please contact:

 

Jim Durward, President, CEO/CTO

Email: jimd@ndatalyze.com    

nDatalyze Website: https://www.ndatalyze.com      

 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.